Trump wants to bring manufacturing back to the US including pharmaceuticals by imposing tariffs. However, that tool could ...

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers and industry experts, who warn that such a move could lead to increased drug ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for ...

With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

These drugs can be divided into generic and biosimilar categories based on their composition. The generic segment is controlled by a few large drugmakers and generic units of large pharma companies.

Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40 ...

Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek ...

the trade group for generic and biosimilar medicine, told CNN. “And that could amplify the drug shortages concerns we have here in the United States.” Currently, there are 270 active drug ...